ASCO GU 2020: Nivolumab plus ipilimumab benefit for advanced kidney cancer
Updated results have been released from the Phase 3 CheckMate -214 study evaluating the combination…
Updated results have been released from the Phase 3 CheckMate -214 study evaluating the combination…